Direct effects of osteoprotegerin on human bone cell metabolism

Biochemical and Biophysical Research Communications

Volumn 389, Issue 3, 2009, Pages 550-555

  Grundt, Alexander ^a   Grafe, Ingo Alexander ^a   Liegibel, Ute ^a   Sommer, Ulrike ^a   Nawroth, Peter ^a   Kasperk, Christian ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Anabolic bone cell metabolism; ERK signaling; Integrins; Mechanoperception; OPG RANKL RANK system; Osteoporosis

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ALPHA5 INTEGRIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; VITRONECTIN RECEPTOR; ALKALINE PHOSPHATASE;

ARTICLE; BONE BIOPSY; BONE CELL; BONE MASS; BONE REMODELING; CELL DIFFERENTIATION; CELL METABOLISM; CONTROLLED STUDY; HUMAN; HUMAN CELL; IN VITRO STUDY; OSTEOCLAST; OSTEOLYSIS; PHENOTYPE; PRIORITY JOURNAL; PROTEIN INTERACTION; PROTEIN PHOSPHORYLATION; VERTEBRA FRACTURE; ANIMAL; BONE; CELL CULTURE; CYTOLOGY; DRUG EFFECT; GENETICS; METABOLISM; MOUSE; OSTEOCYTE; SPINE FRACTURE;

MUS;

ALKALINE PHOSPHATASE; ANIMALS; BONE AND BONES; CELLS, CULTURED; HUMANS; INTEGRIN ALPHAVBETA3; MICE; OSTEOCYTES; OSTEOPROTEGERIN; RANK LIGAND; SPINAL FRACTURES;

EID: 70449726619     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2009.09.026     Document Type: Article

References (34)

1. W.S. Simonet, D.L. Lacey, C.R. Dunstan, et al., Osteoprotegerin: a novel secreted protein involved in the regulation of bone density, Cell 89 (2) (1997) 309-319.
2. T. Akatsu, T. Murakami, K. Ono, et al., Osteoclastogenesis inhibitory factor exhibits hypocalcemic effects in normal mice and in hypercalcemic nude mice carrying tumors associated with humoral hypercalcemia of malignancy, Bone 23 (6) (1998) 495-498.
3. E. Tsuda, M. Goto, S. Mochizuki, et al., Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis, Biochem. Biophys. Res. Commun. 234 (1) (1997) 137-142.
4. Y.Y. Yuan, P.J. Kostenuik, M.S. Ominsky, et al., Skeletal deterioration induced by RANKL infusion: a model for high-turnover bone disease, Osteoporos. Int. 19 (5) (2008) 625-635.
5. N. Bucay, I. Sarosi, C.R. Dunstan, et al., Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification, Genes Dev. 12 (1998) 1260-1268.
6. A.R. Pettit, H. Ji, D. von Stechow, R. Müller, et al., TRANCE/RANKL knockout mice are protected from bone erosion in a serum transfer model of arthritis, Am. J. Pathol. 159 (5) (2001) 1689-1699.
7. W.C. Dougall, M. Glaccum, K. Charrier, et al., RANK is essential for osteoclast and lymph node development, Genes Dev. 13 (18) (1999) 2412-2424.
8. E. Tsuda, M. Goto, S. Mochizuki, et al., Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis, Biochem. Biophys. Res. Commun. 234 (1) (1997) 137-142.
9. T.A. Bateman, C.R. Dunstan, D.L. Lacey, et al., Osteoprotegerin ameliorates sciatic nerve crush induced bone loss, J. Orthop. Res. 19 (4) (2001) 518-523.
10. S. Mochizuki, N. Fujise, K. Higashio, E. Tsuda, Osteoclastogenesis inhibitory factor/osteoprotegerin ameliorates the decrease in both bone mineral density andbonestrength inimmobilized rats, J. BoneMiner. Metab. 20(1) (2002) 14-20.
11. Y. Ichinose, H. Tanaka, M. Inoue, et al., Osteoclastogenesis inhibitory factor/osteoprotegerin reduced bone loss induced by mechanical unloading, Calcif. Tissue Int. 75 (4) (2004) 338-343.
12. H. Dobnig, L.C. Hofbauer, V. Viereck, et al., Changes in the RANK ligand/osteoprotegerin system are correlated to changes in bone mineral density in bisphosphonate-treated osteoporotic patients, Osteoporos. Int. 17 (5) (2006) 693-703.
13. W.S. Rasband, Image J, US National Institutes of Health, Bethesda, Maryland, USA (1997-2008) http://rsb.info.nih.gov/ij/.
14. C.H. Kasperk, G.K. Wakley, T. Hierl, R. Ziegler, Gonadal and adrenal androgens are potent regulators of human bone cell metabolism in vitro, J. Bone Miner. Res. 12 (3) (1997) 464-471.
15. I. Hofmann, M. Schnolzer, I. Kaufmann, W.W. Franke, Symplekin, a constitutive protein of karyo-and cytoplasmic particles involved in mRNA biogenesis in Xenopus laevis oocytes, Mol. Biol. Cell. 13 (2002) 1665-1676.
16. C. Kasperk, J. Hillmeier, G. Nöldge, et al., Treatment of painful vertebral fractures by hypoplasty in patients with primary osteoporosis: a prospective nonrandomized controlled study, J. Bone. Miner. Res. 20 (4) (2005) 604-612.
17. S.K. Tat, M. Padrines, S. Theoleyre, et al., OPG/membranous-RANKL complex is internalized via the clathrin pathway before a lysosomal and a proteasomal degradation, Bone 39 (4) (2006) 706-715.
18. T.C. Register, R.E. Wuthier, Effect of vanadate, a potent alkaline phosphatase inhibitor, on 45Ca and 32Pi uptake by matrix vesicle-enriched fractions from chicken epiphyseal cartilage, J. Biol. Chem. 259 (6) (1984) 3511-3518.
19. W. Beertsen, T. van den Bos, Calcification of dentinal collagen by cultured rabbit periosteum: the role of alkaline phosphatase, Matrix 9 (2) (1989) 159-171.
20. W. Beertsen, T. van den Bos, Alkaline phosphatase induces the mineralization of sheets of collagen implanted subcutaneously in the rat, J. Clin. Invest. 89 (6) (1992) 1974-1980.
21. F.J. Schoen, R.J. Levy, Bioprosthetic heart valve calcification: membranemediated events and alkaline phosphatase, Bone Miner. 17 (2) (1992) 129-133.
22. C.M. Shipman, P.I. Croucher, Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells, Cancer Res. 63 (5) (2003) 912-916.
23. P.J. Kostenuik, V. Shalhoub, Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption, Curr. Pharm. Des. 7 (8) (2001) 613-635.
24. M.E. Lacouture, J.L. Schaffer, L.B. Klickstein, A comparison of type I collagen, fibronectin, and vitronectin in supporting adhesion of mechanically strained osteoblasts, J. Bone Miner. Res. 17 (3) (2002) 481-492.
25. S.M. Frisch, E. Ruoslahti, Integrins and anoikis, Curr. Opin. Cell Biol. 9 (5) (1997) 701-706.
26. S.M. Frisch, K. Vuori, E. Ruoslahti, P.Y. Chan-Hui, Control of adhesion-dependent cell survival by focal adhesion kinase, J. Cell Biol. 134 (3) (1996) 793-799.
27. A. Miyauchi, M. Gotoh, H. Kamioka, et al., AlphaVbeta3 integrin ligands enhance volume-sensitive calcium influx in mechanically stretched osteocytes, J. Bone Miner. Metab. 24 (6) (2006) 498-504.
28. C.F. Lai, S.L. Cheng, Alphavbeta integrins playan essential role in BMP-2 induction of osteoblast differentiation, J. Bone Miner. Res. 20 (2) (2005) 330-340.
29. Y. Wang, L.M. McNamara, M.B. Schaffler, S. Weinbaum, A model for the role of integrins in flow induced mechanotransduction in osteocytes, Proc. Natl. Acad. Sci. USA 104 (40) (2007) 15941-15946.
30. U.M. Liegibel, U. Sommer, P. Tomakidi, et al., Concerted action of androgens and mechanical strain shifts bone metabolism from high turnover into an osteoanabolic mode, J. Exp. Med. 196 (10) (2002) 1387-1392.
31. C.F. Lai, L. Chaudhary, A. Fausto, et al., Erk is essential for growth, differentiation, integrin expression, and cell function in human osteoblastic cells, J. Biol. Chem. 276 (17) (2001) 14443-14450.
32. S. Fiorucci, L. Santucci, R. Gerli, et al., NSAIDs upregulate beta 2-integrin expression on human neutrophils through a calcium-dependent pathway, Aliment. Pharmacol. Ther. 11 (3) (1997) 619-630.
33. D.R. Alessi, A. Cuenda, P. Cohen, et al., PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo, J. Biol. Chem. 270 (46) (1995) 27489-27494.
34. E. Perlson, I. Michaelevski, N. Kowalsman, et al., Vimentin binding to phosphorylated Erk sterically hinders enzymatic dephosphorylation of the kinase, J. Mol. Biol. 364 (5) (2006) 938-944.